Drew Deniger
2023
In 2023, Drew Deniger earned a total compensation of $629.7K as VP, Research and Development at ZIOPHARM Oncology, a 34% decrease compared to previous year.
Compensation breakdown
| Option Awards | $47,888 |
|---|---|
| Salary | $317,757 |
| Other | $264,035 |
| Total | $629,680 |
Deniger received $317.8K in salary, accounting for 50% of the total pay in 2023.
Deniger also received $47.9K in option awards and $264K in other compensation.
Rankings
In 2023, Drew Deniger's compensation ranked 1,739th out of 2,918 executives tracked by ExecPay. In other words, Deniger earned more than 40.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,739 out of 2,918 | 40th |
Division Manufacturing | 1,014 out of 1,608 | 37th |
Major group Chemicals And Allied Products | 638 out of 901 | 29th |
Industry group Drugs | 622 out of 864 | 28th |
Industry Pharmaceutical Preparations | 445 out of 622 | 29th |
Source: SEC filing on April 26, 2024.
Deniger's colleagues
We found two more compensation records of executives who worked with Drew Deniger at ZIOPHARM Oncology in 2023.